Clinical outcome of patients with stable ischaemic heart disease as compared to those with acute coronary syndromes after percutaneous coronary intervention by Vranckx, Pascal et al.
C L I N I C A L  R E S E A R C H
CORONARY  INTERVENT IONS
E
u
roIn
te
rve
n
tio
n
 2
0
1
5
;1
1
:1
7
1
-1
7
9
   
D
O
I: 1
0
.4
2
4
4
/E
IJ
V
1
1
I2
A
3
1
171
© Europa Digital & Publishing 2015. All rights reserved.
*Corresponding author: Ba583a, Thoraxcenter, Erasmus MC, ‘s-Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands. 
E-mail: p.w.j.c.serruys@erasmusmc.nl
Clinical outcome of patients with stable ischaemic heart 
disease as compared to those with acute coronary 
syndromes after percutaneous coronary intervention
Pascal Vranckx1,3,6, MD, PhD; Bindu Kalesan2, MSc; Giulio G. Stefanini4, MD; Vasim Farooq3, MBChB; 
Yoshinobu Onuma3, MD; Sigmund Silber5, MD; Ton de Vries6, MSc; Peter Jüni2,7, MD; 
Patrick W. Serruys3*, MD, PhD; Stephan Windecker4,7, MD
1. Department of Cardiac Intensive Care & Interventional Cardiology, Hartcentrum, Hasselt, Belgium; 2. Institute of Social and 
Preventive Medicine, University of Bern, Bern, Switzerland; 3. Department of Cardiology, Thoraxcenter, Erasmus MC, 
Rotterdam, The Netherlands; 4. Department of Cardiology, Bern University Hospital, Bern, Switzerland; 5. Heart Center at the 
Isar, Munich, Germany; 6. Cardialysis Clinical Research Management & Core Laboratories, Rotterdam, The Netherlands; 
7. Clinical Trials Unit, Bern University Hospital, Bern, Switzerland
GUEST EDITOR: Ron Waksman, MD; Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC, USA
Abstract
Aims: To compare clinical outcomes after percutaneous coronary intervention (PCI) between patients with 
acute coronary syndromes (ACS) and those with stable ischaemic heart disease (SIHD) stratified by anatomic 
disease complexity (SYNTAX score).
Methods and results: Patient-level data from three all-comers PCI trials were pooled. Patients (n=4,204) 
were stratified by clinical presentation (i.e., ACS or SIHD) and by SYNTAX score (i.e., lowest vs. two high-
est tertiles). The major adverse cardiac event (MACE) rates of patients with low-risk SIHD (n=531) and 
high-risk SIHD (n=1,066) were compared with ACS patients (n=2,607), respectively. At two years, the risk 
of MACE was higher for high-risk SIHD patients (OR 1.34, 95% CI: 1.08-1.66) and lower for low-risk SIHD 
patients (OR 0.61, 95% CI: 0.43-0.87) compared with ACS patients, respectively. This difference between 
high-risk SIHD patients and ACS patients was primarily driven by a higher risk of myocardial infarction (OR 
1.64, 95% CI: 1.21-2.21), while there was no difference for cardiac death (OR 0.77, 95% CI: 0.49-1.21) or 
target lesion revascularisation (OR 1.21, 95% CI: 0.91-1.62).
Conclusions: In this pooled analysis, the majority of patients undergoing PCI for SIHD (i.e., 
with SYNTAX score >8) had a higher risk of MACE than patients with ACS. Trial registration: URL: 
http://www.ClinicalTrials.gov; unique identifier: NCT00297661 (Sirtax), NCT00389220 (Leaders), 
NCT00114972 (Resolute-AC).
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Introduction
Treatment of obstructive coronary lesions causing ischaemia by 
means of percutaneous coronary intervention (PCI) with stent 
implantation improves functional status and clinical outcomes1-4. 
The expanding indications for PCI, coupled with refinements 
in technology, including the introduction of drug-eluting stents 
(DES) and more intensive adjunctive pharmacological treatment, 
have resulted in the treatment of increasingly complex lesions and 
patients with a history of established cardiovascular disease, coex-
isting morbidities, and complex coronary anatomy in recent years5-7. 
Complex lesions and patient subsets were excluded from the initial 
coronary stent studies. More recently, however, large-scale investi-
gations of stent technology have been performed in the context of 
so-called “all-comers” patient populations allowing the unrestricted 
use of DES8-11.
All-comers studies provide an opportunity to compare clini-
cal outcomes among patients presenting with and without acute 
coronary syndromes (ACS) in the context of a randomised trial. 
Noteworthy, careful risk assessment based on clinical and angio-
graphic characteristics is used to guide decision making regarding 
type of therapeutic intervention, triage among hospital care levels, 
and allocation of clinical resources12-14. Therefore, identification of 
higher-risk patients remains of paramount importance. Patients pre-
senting with ACS are currently considered to be at high risk of major 
adverse cardiac events (MACE) during short- and long-term follow-
up, and therefore receive aggressive pharmacotherapy15. However, 
patients with stable ischaemic heart disease (SIHD) include a broad 
spectrum of anatomic disease complexity, which – as assessed 
by the SYNTAX score – has been shown to be predictive of out-
comes16-18. To date, no data are available comparing outcomes after 
PCI between patients with ACS and stable CAD stratified by ana-
tomic disease complexity. Against this background, we compared 
clinical outcomes between patients with ACS and those with SIHD 
stratified into high and low-risk cohorts according to the angio-
graphic SYNTAX score.
Methods
STUDY POPULATION
Individual data were pooled for 5,011 patients from three large 
randomised clinical trials investigating the unrestricted use of 
DES for coronary revascularisation: the Sirolimus-Eluting and 
Paclitaxel-Eluting Stent for Coronary Revascularization (SIRTAX; 
n=1,012) trial9, the Biolimus-Eluting Stent with Biodegradable 
Polymer versus Sirolimus-Eluting Stent with Durable Polymer 
for Coronary Revascularisation (LEADERS; n=1,707) trial10, and 
the Comparison of Zotarolimus-Eluting and Everolimus-Eluting 
Coronary Stents (RESOLUTE AC; n=2,292) trial11. All trials 
were conducted between 2004 and 2009 at European institutions, 
with the unrestricted use of DES and an all-comers study design. 
Inclusion criteria were broad in order to reflect routine clini-
cal practice. Patients with either stable coronary artery disease or 
acute coronary syndromes (including patients with unstable angina, 
non-ST-segment elevation and ST-segment elevation myocardial 
infarction) were eligible, if they had at least one lesion with diam-
eter stenosis of 50% or more in a vessel with reference diameter of 
2.25 to 4.0 mm (SIRTAX and RESOLUTE all-comers) and 2.25 to 
3.5 mm (LEADERS). None of the trials had any restriction with 
respect to number of treated lesions, treated vessels, lesion length, 
or number of stents implanted. Exclusion criteria were few and 
included known intolerance to the study drugs, metal alloys or con-
trast media, planned surgery within six months after the index pro-
cedure, and participation in another study. Angiographic follow-up 
was planned at eight months among patients included in SIRTAX, 
at nine months among 25% of patients included in LEADERS, and 
at 13 months among 20% of patients in RESOLUTE-AC. The angi-
ographic SYNTAX score at baseline was determined in each of the 
trials. The trials complied with the provisions of the Declaration 
of Helsinki, and the study protocols were approved by the institu-
tional review board at each study centre. All patients provided writ-
ten informed consent for participation in the study.
PROCEDURES
Randomisation was done after diagnostic angiography and before 
PCI in all three trials. In the SIRTAX trial patients were randomly 
allocated to receive sirolimus-eluting stents (CYPHER®; Cordis, 
Johnson & Johnson, Miami Lakes, FL, USA) or paclitaxel-eluting 
stents (TAXUS™; Boston Scientific, Natick, MA, USA), in the 
LEADERS trial patients were randomly allocated to receive bioli-
mus-eluting stents (BioMatrix™; Biosensors Inc., Newport Beach, 
CA, USA) or sirolimus-eluting stents (CYPHER®; Cordis, Johnson 
& Johnson), and in the RESOLUTE-AC trial patients were ran-
domly allocated to receive zotarolimus-eluting stents (Endeavor® 
Resolute; Medtronic Inc., Santa Rosa, CA, USA) or everolimus-
eluting stents (XIENCE V®; Abbott Vascular, Santa Clara, CA, 
USA). Balloon angioplasty and stent implantation were per-
formed according to standard techniques and in accordance with 
guidelines; direct stenting was allowed. Full lesion coverage was 
attempted by implanting one or several stents. No mixture of types 
of stent was permitted for a given patient unless the operator was 
unable to insert the study stent, in which case crossover to another 
device of the operator’s choice was possible. In case of unplanned 
revascularisation procedures requiring stent implantation, it was 
recommended that physicians use the same type as the initially 
allocated study stent. Procedural anticoagulation was achieved with 
unfractionated heparin at a dose of 5,000 IU or 70 to 100 IU per 
kilogram of body weight; the use of glycoprotein IIb/IIIa inhibitors 
was left to the operator’s discretion. Dual antiplatelet therapy con-
sisting of acetylsalicylic acid of at least 75 mg once daily and the 
thienopyridine clopidogrel 75 mg daily was prescribed for at least 
12 months in SIRTAX and LEADERS, and for at least six months 
in the RESOLUTE-AC trial.
DEFINITIONS
The main outcome measure of the present study was the risk of 
MACE, defined as a composite of cardiac death, myocardial infarc-
tion (MI), and ischaemia-driven target lesion revascularisation 
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PCI in high and low-risk stable patients vs. ACS patients
(TLR). Secondary outcomes were the individual components of 
MACE as well as all-cause death, target vessel revascularisation, as 
well as definite and definite/probable stent thrombosis according to 
the Academic Research Consortium criteria19.
For each trial, a blinded clinical events committee independently 
adjudicated all adverse events. Endpoint definitions were compa-
rable across the three trials. Cardiac death was defined as death 
from cardiac causes or any death from unknown causes in SIRTAX 
and LEADERS, and as any death unless an undisputed non-car-
diac cause was present in RESOLUTE-AC. MI was defined – in the 
SIRTAX and LEADERS trials – as the presence of new Q-waves 
in at least two contiguous leads and an elevated creatine kinase 
MB fraction, or – in the absence of significant Q-waves – as an 
increase in the creatine kinase level to more than twice the upper 
limit of the normal range with an elevated level of creatine kinase 
MB or troponin9,10. In the RESOLUTE-AC trial MI was defined 
according to an “extended historical” definition consistent with the 
one used in SIRTAX and LEADERS20. Target lesion revascularisa-
tion was defined as any revascularisation for a stenosis within the 
stent or within a 5 mm border proximal and distal to the stent in all 
three trials. A revascularisation was considered ischaemia-driven in 
the presence of angiographic diameter stenosis of at least 50% and 
ischaemic signs or symptoms, or with angiographic diameter steno-
sis of at least 70% regardless of ischaemic signs or symptoms9-11.
The SYNTAX score for each patient was calculated prospec-
tively by scoring all coronary lesions with a DS ≥50%, in vessels 
≥1.5 mm, using the SYNTAX score algorithm which is described 
in full elsewhere16,21, and available at www.syntaxscore.com. All 
angiographic variables pertinent to SYNTAX score calculation 
were computed by two analysts from a core laboratory (Cardialysis 
B.V., Rotterdam, The Netherlands), blinded to clinical presenta-
tion and outcomes. In the event of disagreement, the opinion of 
a third analyst was sought, and the final decision was established 
by consensus. As previously described17,22-24, patients with occluded 
infarct-related arteries were scored as having occlusions of 
unknown duration in a similar manner to any chronically occluded 
artery. In addition, those patients with lesions due to restenosis were 
scored in the same manner as de novo lesions.
STATISTICAL ANALYSIS
From a total of 5,011 randomised patients, 4,204 (84%) patients with 
a calculated preprocedural SYNTAX score completed two years of 
follow-up and were included in the present analysis. Patients were 
stratified according to baseline clinical presentation (i.e., ACS or 
SIHD). Patients with SIHD were further stratified by SYNTAX score 
(i.e., higher tertiles [SYNTAX score >8] or lower tertile [SYNTAX 
score ≤8])17. Clinical outcomes of patients with SIHD at low risk and 
at high risk were compared with patients with ACS, respectively. 
Clinical outcomes were compared overall, as well as according to 
a landmark analysis at 30 days and after stratification by gender. 
Mixed regression models were used with type of randomised clinical 
trial as the random intercept and treatment arms as the random coef-
ficient. Percentages were predicted probabilities derived from mixed 
maximum logistic regression models for the categorical variables, 
whereas mean and standard deviations (SD) were predicted from 
the mixed likelihood regression models for the continuous covari-
ates. All the odds ratios (OR) and 95% confidence intervals (CI) 
were adjusted for stent type. Cumulative incidence curves were con-
structed using the Kaplan-Meier methodology and compared using 
the log-rank test. A sensitivity analysis was performed by excluding 
periprocedural MI, defined as any non-Q-wave MI occurring within 
48 hours after PCI not associated with definite stent thrombosis. 
All analyses are by intention to treat, performed using STATA 11.2 
(StataCorp LP, College Station, TX, USA).
Results
From a total of 4,204 patients, 2,607 (62%) patients presented with 
ACS, 1,066 (25%) patients with stable, high-risk coronary artery dis-
ease, and 531 (13%) patients with stable, low-risk coronary artery 
disease. Baseline clinical characteristics of the three groups are sum-
marised in Table 1. Low-risk SIHD patients were older (p<0.0001), 
more likely to be female (p=0.014), more frequently had hypertension 
(p<0.0001), hypercholesterolaemia, and previous PCI (p<0.0001), 
and less frequently had smoking habits (p<0.0001), previous coronary 
artery bypass grafting (p=0.028), multivessel disease (p<0.0001), and 
impaired left ventricular systolic function (p<0.0001) compared with 
ACS patients. High-risk SIHD patients were older (p<0.0001), more 
frequently had diabetes mellitus (p<0.0001), hypertension (p<0.0001), 
hypercholesterolaemia (p<0.0001), previous MI (p<0.0001), previous 
PCI (p<0.0001), multivessel disease (p<0.0001), and less frequently 
had smoking habits (p<0.0001), previous coronary artery bypass 
grafting (p<0.0001) and impaired left ventricular systolic function 
(p<0.0001), compared with ACS patients.
Angiographic and procedural characteristics are summarised 
in Table 2. Low-risk SIHD patients more frequently had the right 
coronary artery and less frequently a bypass graft as target lesion 
(p<0.0001), and less frequently had de novo lesions (p=0.006), 
moderately or severely calcified lesions (p=0.033), and total occlu-
sions (p<0.0001), compared with ACS patients. Conversely, high-
risk SIHD patients more frequently had the left anterior descending 
and less frequently a bypass graft as target vessel (p<0.0001), more 
frequently had moderate or severe calcified lesions (p<0.0001), and 
less frequently had de novo lesions (p=0.01) and total occlusions 
(p<0.0001), compared with ACS patients.
Clinical outcomes up to two years are reported in Table 3, overall 
and according to a landmark analysis at 30 days. Cumulative inci-
dence curves for MACE up to two years are shown in Figure 1. At 
two years, the risk of MACE was lower for low-risk SIHD patients 
(OR 0.61, 95% CI: 0.43-0.87) and higher for high-risk SIHD 
patients (OR 1.34, 95% CI: 1.08-1.66), respectively, compared with 
ACS patients. Low-risk SIHD patients had a markedly reduced risk 
of cardiac death (OR 0.22, 95% CI: 0.08-0.59) and similar risks 
of MI (OR 0.85, 95% CI: 0.52-1.38) and TLR (OR 0.66, 95% CI: 
0.42-1.03), compared with ACS patients.
The differences between high-risk SIHD and ACS patients 
were primarily driven by a higher risk of MI (OR 1.64, 95% CI: 
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1.21-2.21), whereas no differences were observed for cardiac death 
(OR 0.77, 95% CI: 0.49-1.21) and TLR (OR 1.21, 95% CI: 0.91-
1.62). Landmark analyses showed that high-risk SIHD patients 
compared with ACS patients had an increased risk of MI during 
the first 30 days (OR 1.89, 95% CI: 1.35-2.66) without differences 
beyond 30 days up to two years (OR 1.00, 95% CI: 0.54 to 1.88). 
No differences between groups were observed with respect to stent 
thrombosis up to two years, as summarised in Table 4.
Risks of MACE and its individual components at two years strat-
ified by gender are summarised in Figure 2 and Figure 3. Female 
high-risk SIHD patients had a higher risk of MACE compared with 
female ACS patients at two years, whereas the risk of MACE was 
similar among male high-risk SIHD and ACS patients. However, 
formal tests for interaction were negative (p-interaction=0.22). 
Noteworthy, female high-risk SIHD patients had a higher risk of 
MI compared with female ACS patients (OR 2.80, 95% CI: 1.64-
4.79), whereas no differences were noted among male patients (OR 
1.25, 95% CI: 0.86-1.82) with formal tests for interaction resulting 
as positive (p-interaction=0.012).
Sensitivity analyses showed that differences disadvantaging high-
risk SIHD compared with ACS patients with respect to MACE (OR 
1.23, 95% CI: 0.97-1.55) and MI (OR 0.85, 95% CI: 0.51-1.43) at 
two years were no longer evident by excluding periprocedural MI.
Discussion
This individual patient data pooled analysis of three large contem-
porary trials including all-comer patients undergoing PCI with the 
unrestricted use of drug-eluting stents has the following findings:
Table 1.  Baseline clinical characteristics.
Low-risk SIHD High-risk SIHD ACS
Low-risk SIHD vs. ACS High-risk SIHD vs. ACS
Difference (95% CI) p Difference (95% CI) p
No. of patients 531 1,066 2,607
Age 64.6 (9.9) 65.3 (10.4) 62.8 (11.3) 1.9 (0.9 to 3.0) <0.0001 2.5 (1.8 to 3.3) <0.0001
Female 154 (29.0) 261 (24.5) 624 (23.9) 5.1 (1.0 to 9.1) 0.014 0.5 (–2.5 to 3.6) 0.724
Diabetes 120 (22.6) 285 (26.7) 516 (19.8) 2.8 (–0.8 to 6.4) 0.125 6.9 (4.0 to 9.9) <0.0001
Insulin-requiring diabetes 45 (37.5) 84 (29.5) 179 (34.7) 2.8 (–6.7 to 12.3) 0.562 –5.2 (–12.0 to 1.6) 0.133
Obese 157 (29.6) 257 (24.2) 663 (25.6) 4.0 (0.1 to 8.0) 0.046 –1.4 (–4.6 to 1.7) 0.375
Renal impairment (eGFR <60) 76 (14.3) 167 (15.7) 354 (13.6) 0.7 (–1.9 to 3.3) 0.579 2.1 (–0.4 to 4.5) 0.095
Hypertension 395 (74.4) 799 (75.0) 1,719 (65.9) 8.5 (4.6 to 12.3) <0.0001 9.0 (5.8 to 12.3) <0.0001
Hypercholesterolaemia 381 (71.8) 757 (71.0) 1,505 (57.7) 14.0 (9.7 to 18.4) <0.0001 13.3 (9.8 to 16.7) <0.0001
Current smoking 123 (23.2) 212 (19.9) 884 (33.9) –10.8 (–14.8 to –6.7) <0.0001 –14.0 (–17.3 to –10.8) <0.0001
Previous MI 149 (28.2) 343 (32.6) 691 (26.7) 1.5 (–2.9 to 6.0) 0.501 5.9 (2.7 to 9.2) <0.0001
Previous PCI 199 (37.5) 402 (37.7) 602 (23.1) 14.4 (10.6 to 18.2) <0.0001 14.6 (11.5 to 17.8) <0.0001
Previous CABG 22 (4.1) 16 (1.5) 182 (7.0) –2.8 (–5.4 to –0.3) 0.028 –5.5 (–7.3 to –3.7) <0.0001
LVEF <0.50 55 (13.0) 109 (14.5) 479 (27.2) –14.2 (–18.9 to –9.5) <0.0001 –12.7 (–16.4 to –8.9) <0.0001
Multivessel disease 31 (5.8) 278 (26.1) 491 (18.8) –13.0 (–17.1 to –8.9) <0.0001 7.3 (4.6 to 10.0) <0.0001
Values are n (%). ACS: acute coronary syndromes; CABG: coronary artery bypass grafting; eGFR: estimated glomerular filtration rate; High-risk SIHD : high-risk stable ischaemic heart 
disease; Low-risk SIHD : low-risk stable ischaemic heart disease; LVEF: left ventricular ejection fraction; PCI: percutaneous coronary intervention
Table 2. Baseline angiographic characteristics.
Low-risk SIHD High-risk SIHD ACS
Low-risk SIHD vs. ACS High-risk SIHD vs. ACS
Difference (95% CI) p Difference (95% CI) p
No. of lesions 843 1,469 3,777
Target vessel <0.0001 <0.0001
Left main 2 (0.2) 15 (1.0) 52 (1.4) –1.1 (–2.5 to 0.3) –0.4 (–1.7 to 1.0)
Left anterior descending 303 (35.9) 683 (46.5) 1,535 (40.6) –4.7 (–5.0 to –4.4) 5.9 (5.6 to 6.2)
Left circumflex 193 (22.9) 344 (23.4) 889 (23.5) –0.6 (–0.9 to –0.4) –0.1 (–0.4 to 0.2)
Right coronary artery 335 (39.7) 426 (29.0) 1,227 (32.5) 7.3 (7.0 to 7.5) –3.5 (–3.7 to –3.2)
Bypass graft 10 (1.2) 0 (0.0) 74 (2.0) –0.8 (–1.3 to –0.3) –2.0 (–2.5 to –1.5)
De novo lesions 772 (92.0) 1,349 (92.6) 3,556 (94.5) –2.5 (–2.6 to –2.4) 0.006 –1.9 (–2.0 to –1.8) 0.01
Total occlusion 15 (1.8) 111 (7.7) 716 (19.1) –17.3 (–18.3 to –16.3) <0.0001 –11.5 (–12.1 to –10.8) <0.0001
Moderate or severe calcification 132 (15.8) 379 (26.1) 707 (18.9) –3.2 (–3.3 to –3.0) 0.033 7.2 (6.8 to 7.6) <0.0001
Values are n (%). ACS: acute coronary syndromes; High-risk SIHD: high-risk stable ischaemic heart disease; Low-risk SIHD: low-risk stable ischaemic heart disease
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Table 3. Clinical outcomes up to 2 years.
Low-risk SIHD 
(N=531)
High-risk SIHD 
(N=1,066)
ACS
(N=2,607)
Low-risk SIHD vs. ACS High-risk SIHD vs. ACS
OR (95% CI) p OR (95% CI) p
Overall
Death 12 (2.3) 33 (3.1) 112 (4.3) 0.47 (0.26 to 0.87) 0.015 0.70 (0.47 to 1.04) 0.081
Cardiac death 4 (0.8) 26 (2.4) 81 (3.1) 0.22 (0.08 to 0.59) 0.003 0.77 (0.49 to 1.21) 0.261
MI 20 (3.8) 75 (7.0) 115 (4.4) 0.85 (0.52 to 1.38) 0.515 1.64 (1.21 to 2.21) 0.001
Ischaemia-driven TVR 29 (5.5) 91 (8.5) 183 (7.0) 0.68 (0.45 to 1.02) 0.062 1.23 (0.95 to 1.61) 0.118
Ischaemia-driven TLR 24 (4.5) 75 (7.0) 153 (5.9) 0.66 (0.42 to 1.03) 0.070 1.21 (0.91 to 1.62) 0.192
Cardiac death or MI 21 (4.0) 94 (8.8) 179 (6.9) 0.54 (0.34 to 0.86) 0.009 1.31 (1.01 to 1.70) 0.043
MACE 39 (7.3) 148 (13.9) 280 (10.7) 0.61 (0.43 to 0.87) 0.006 1.34 (1.08 to 1.66) 0.008
0 to 30 days
Death 0 (0.0) 5 (0.5) 25 (1.0) 0.00 0.994 0.48 (0.18 to 1.25) 0.132
Cardiac death 0 (0.0) 5 (0.5) 20 (0.8) 0.00 0.978 0.60 (0.22 to 1.60) 0.306
MI 15 (2.8) 61 (5.7) 81 (3.1) 0.94 (0.54 to 1.65) 0.839 1.89 (1.35 to 2.66) 0.001
Ischaemia-driven TVR 5 (0.9) 19 (1.8) 48 (1.8) 0.48 (0.19 to 1.21) 0.121 0.97 (0.57 to 1.66) 0.920
Ischaemia-driven TLR 4 (0.8) 17 (1.6) 45 (1.7) 0.40 (0.14 to 1.13) 0.083 0.93 (0.53 to 1.63) 0.792
Cardiac death or MI 15 (2.8) 64 (6.0) 98 (3.8) 0.76 (0.44 to 1.32) 0.332 1.63 (1.18 to 2.26) 0.003
MACE 16 (3.0) 71 (6.7) 113 (4.3) 0.70 (0.41 to 1.19) 0.182 1.57 (1.16 to 2.14) 0.004
31 days to 2 years
Death 12 (2.3) 28 (2.6) 87 (3.3) 0.61 (0.33 to 1.13) 0.119 0.77 (0.50 to 1.19) 0.247
Cardiac death 4 (0.8) 21 (2.0) 61 (2.3) 0.29 (0.10 to 0.80) 0.017 0.84 (0.51 to 1.38) 0.482
MI 5 (0.9) 14 (1.3) 34 (1.3) 0.65 (0.25 to 1.68) 0.376 1.00 (0.54 to 1.88) 0.988
Ischaemia-driven TVR 24 (4.5) 72 (6.8) 135 (5.2) 0.76 (0.48 to 1.19) 0.226 1.32 (0.98 to 1.78) 0.067
Ischaemia-driven TLR 20 (3.8) 58 (5.4) 108 (4.1) 0.78 (0.48 to 1.27) 0.316 1.33 (0.95 to 1.85) 0.093
Cardiac death or MI 6 (1.1) 30 (2.8) 81 (3.1) 0.32 (0.14 to 0.74) 0.007 0.90 (0.59 to 1.38) 0.628
MACE 23 (4.3) 77 (7.2) 167 (6.4) 0.58 (0.37 to 0.90) 0.016 1.13 (0.86 to 1.50) 0.382
Values are n (%). ACS: acute coronary syndromes; CI: confidence interval; High-risk SIHD: high-risk stable ischaemic heart disease; Low-risk SIHD: low-risk stable ischaemic heart 
disease; MACE: major adverse cardiac events; MI: myocardial infarction; OR: odds ratio; TLR: target lesion revascularisation; TVR: target vessel revascularisation
Table 4. Stent thrombosis up to 2 years.
Low-risk SIHD 
(N=531)
High-risk SIHD 
(N=1,066)
ACS (N=2,607)
Low-risk SIHD vs. ACS High-risk SIHD vs. ACS
OR (95% CI) p OR (95% CI) p
Definite
Early 3 (0.5) 9 (0.9) 35 (1.3) 1.89 (0.51 to 7.03) 0.342 0.66 (0.32 to 1.38) 0.273
Late 1 (0.2) 2 (0.2) 7 (0.3) 1.21 (0.11 to 13.46) 0.876 0.73 (0.15 to 3.51) 0.693
Very late 0 (0) 5 (0.5) 10 (0.4) – – 1.28 (0.43 to 3.75) 0.656
Overall 4 (0.7) 16 (1.6) 52 (2.0) 2.56 (0.85 to 7.70) 0.095 0.79 (0.45 to 1.39) 0.411
Definite or probable
Early 3 (0.5) 12 (1.2) 47 (1.8) 2.52 (0.71 to 8.98) 0.154 0.65 (0.34 to 1.24) 0.191
Late 2 (0.3) 3 (0.3) 9 (0.3) 0.86 (0.14 to 5.16) 0.865 0.86 (0.23 to 3.17) 0.815
Very late 0 (0) 5 (0.5) 11 (0.4) – – 1.17 (0.40 to 3.37) 0.775
Overall 5 (0.9) 20 (2.0) 67 (2.6) 2.52 (0.94 to 6.76) 0.067 0.76 (0.46 to 1.26) 0.293
Values are n (%). ACS: acute coronary syndromes; CI: confidence interval; High-risk SIHD: high-risk stable ischaemic heart disease; Low-risk SIHD: 
low-risk stable ischaemic heart disease; OR: odds ratio
1. Patients with SIHD had a high baseline angiographic risk esti-
mate in up to two thirds of cases.
2. High-risk SIHD patients showed a higher risk of MACE com-
pared with ACS patients up to two years of follow-up, mainly due 
to a higher risk of MI occurring within the first 30 days after PCI.
3. The increased risk of MI was particularly pronounced among 
female high-risk SIHD patients.
4. Excluding MI within the first 30 days after PCI, the risk of MI 
was similar among high-risk SIHD and ACS patients up to two 
years.
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Patients undergoing PCI for ACS are regarded as a group at 
increased risk of further cardiac ischaemic events25 and have been 
excluded from early trials investigating DES. More recent ran-
domised studies investigating the unrestricted use of DES applied 
an all-comers design, therefore extending recruitment also to ACS 
patients (including non-ST-elevation and ST-elevation ACS)8-11. 
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SHR 805 749 727 710 720 696 538
ACS 1,983 1,875 1,833 1,797 1,781 1,768 1,381
SLR 377 363 360 350 347 345 290
High-risk SIHD vs. ACS
OR 1.23 (95% CI: 0.96 to 1.59)
Low-risk SIHD vs. ACS
OR 0.66 (95% CI: 0.44 to 0.99)
No. at risk
SHR 261 231 225 219 218 217 162
ACS 624 582 571 558 555 551 432
SLR 154 150 146 145 144 144 110
High-risk SIHD vs. ACS
OR 1.63 (95% CI: 1.09 to 2.46)
Low-risk SIHD vs. ACS
OR 0.48 (95% CI: 0.23 to 0.98)
WomenMen
Figure 2. Major adverse cardiac events up to 2 years stratified by gender. Cumulative incidence curves of the main outcome measure MACE 
up to 2 years of follow-up. ACS: acute coronary syndromes; CI: confidence interval; High-risk SIHD: high-risk stable ischaemic heart 
disease; Low-risk SIHD: low-risk stable ischaemic heart disease; OR: odds ratio; SHR: stable high-risk; SLR: stable low-risk
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SHR 1,066 980 952 929 920 913 700
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High-risk SIHD vs. ACS
OR 1.34 (95% CI: 1.08 to 1.66)
Low-risk SIHD vs. ACS
OR 0.61 (95% CI: 0.43 to 0.87)
Figure 1. Major adverse cardiac events up to 2 years. Cumulative 
incidence curves of the main outcome measure MACE up to 2 years 
of follow-up. ACS: acute coronary syndromes; CI: confidence 
interval; High-risk SIHD: high-risk stable ischaemic heart disease; 
Low-risk SIHD: low-risk stable ischaemic heart disease; OR: odds 
ratio; SHR: stable high-risk; SLR: stable low-risk
The SIRTAX, LEADERS, and RESOLUTE-AC trials, pooled in 
this individual patient data analysis, are three large all-comers tri-
als more closely representing treatment in routine clinical prac-
tice9-11. Noteworthy, rates of death of ACS patients included in this 
pooled analysis (4.3%) were comparable with those observed in 
contemporary ACS trials such as TRITON-TIMI 3815 (3.0%) and 
PLATO26 (4.5%), underscoring the representative nature of the pre-
sent patient population.
Our findings indicate that a substantial proportion of patients 
with SIHD undergoing elective PCI have a higher risk of MACE 
compared with ACS patients at 30 days and two years of follow-
up. Although the difference was mainly due to periprocedural 
MI, it is interesting that, by excluding the latter high-risk SIHD 
patients, a similar risk of MACE compared with ACS patients 
was maintained. This result points to the fact that high-risk SIHD 
patients need to be considered as being at least at similar risk to 
ACS patients, and that they might benefit from more intense phar-
macotherapy and secondary prevention currently reserved to ACS 
patients. High-risk SIHD patients have not been investigated in 
dedicated randomised clinical trials, and therefore there are limited 
grounds for evidence-based treatment guidelines and the potential 
for undertreatment.
In our study, high-risk SIHD patients and ACS patients differed 
in baseline clinical and angiographic characteristics, underlining 
a different coronary atherosclerotic burden. Therefore, the patho-
physiologic mechanisms leading to the increased risk of MACE in 
high-risk SIHD patients and ACS patients might differ. While the 
importance of an aggressive risk factor management is expected to 
be critical for both groups, the therapeutic impact of adjunctive and 
preventive pharmacotherapy remains speculative and needs to be 
addressed in future studies.
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PCI in high and low-risk stable patients vs. ACS patients
The key difference in MACE as it relates to periprocedural MI 
observed in our analysis raises two relevant issues. First, the adju-
dication of periprocedural MI is difficult in ACS patients due to 
the elevated preprocedural cardiac biomarkers. The critical chal-
lenge is to distinguish whether a new cardiac biomarker elevation 
is induced by the PCI procedure (e.g., extension of ischaemia, 
new procedural flow-limiting complications, etc.) or if the car-
diac biomarker release is the tail of the ongoing initial insult27. 
Second, the clinical relevance of periprocedural MI remains prob-
lematic. In the three trials pooled in this analysis, the MI defini-
tion was based on CK-MB, which is less sensitive than troponins; 
however, the threshold used for MI definition was relatively low. 
Post-procedural cardiac biomarker elevation is more debated. 
To date, there is no evidence of impaired long-term clinical out-
comes among SIHD patients with post-procedural cardiac bio-
marker elevation without symptoms or electrocardiographic signs 
of ischaemia27. Noteworthy, the recently released revised version 
of the universal definition of MI document recommends a post-
procedural threshold higher than the one used in our study (i.e., 5x 
upper reference limit)25.
Of note, the excessive risk of MI was particularly pronounced 
among female high-risk SIHD patients compared with female ACS 
patients, whereas no significant difference among male patients 
was noted. The observed positive interaction suggests that this dif-
ference is above that which might have been expected by chance 
alone. A sex-related difference in response to procedural triggers of 
myocardial injury may be possible. Nevertheless, this finding needs 
to be cautiously interpreted in the light of its observational nature 
as well as the debated clinical relevance of post-procedural cardiac 
biomarker elevation28.
Limitations
This analysis has a number of limitations. First, it is a post hoc analysis 
of trials not primarily intended to investigate differences based on clini-
cal indication for PCI. However, the large size, the all-comers nature 
of the study population, and the core-lab assessment of baseline char-
acteristics provide a unique opportunity to compare outcomes of ACS 
patients with those of SIHD patients. Second, the relatively low event 
rates make our findings prone to chance. However, these rates are con-
sistent with real-world contemporary clinical practice. Moreover, the 
observation that the cumulative risk of MACE and its individual com-
ponents among the different groups point in the same direction supports 
the robustness of our findings. Third, this post hoc analysis was not 
powered for multiple effects modification. Therefore, our findings must 
be regarded as exploratory and hypothesis-generating until confirmed 
by evidence from rigorously conducted prospective randomised trials.
Conclusions
In this pooled analysis of three large contemporary trials the major-
ity of patients undergoing elective PCI for SIHD had a higher risk 
of MACE than patients with ACS during long-term follow-up. This 
was primarily due to a higher risk of MI among high-risk SIHD 
patients during the first 30 days, and was particularly pronounced 
among female high-risk SIHD patients.
High-risk
SIHD ACS
(N=1,066) (N=2,607) OR (95% CI) p p-inter
Death 0.72
Women 9 (3.5) 27 (4.3) 0.77 (0.36 to 1.67) 0.51
Men 24 (3.0) 85 (4.3) 0.67 (0.42 to 1.07) 0.094
Cardiac death 0.45
Women 8 (3.1) 19 (3.0) 0.99 (0.42 to 2.30) 0.98
Men 18 (2.2) 62 (3.1) 0.69 (0.41 to 1.18) 0.18
MI 0.012
Women 31 (11.9) 28 (4.5) 2.80 (1.64 to 4.79) 0.0002
Men 44 (5.5) 87 (4.4) 1.25 (0.86 to 1.82) 0.24
Ischaemia·driven TVR 0.81
Women 20 (7.7) 42 (6.7) 1.18 (0.67 to 2.06) 0.56
Men 71 (8.8) 141 (7.1) 1.26 (0.93 to 1.70) 0.14
Ischaemia·driven TLR 0.63
Women 18 (6.9) 41 (6.6) 1.08 (0.61 to 1.93) 0.79
Men 57 (7.1) 112 (5.7) 1.26 (0.91 to 1.76) 0.17
Cardiac death or MI 0.032
Women 35 (13.4) 45 (7.2) 1.95 (1.22 to 3.12) 0.005
Men 59 (7.3) 134 (6.8) 1.08 (0.79 to 1.49) 0.62
MACE 0.22
Women 45 (17.2) 70 (11.2) 1.63 (1.09 to 2.46) 0.019
Men 103 (12.8) 210 (10.6) 1.23 (0.96 to 1.59) 0.11
0.2 0.5 1 2 5
SHR better ACS better
Figure 3. Risks of MACE and its individual components at 2 years stratified by gender. ACS: acute coronary syndromes; CI: confidence 
interval; High-risk SIHD: high-risk stable ischaemic heart disease; OR: odds ratio; SHR: stable high-risk; TLR: target lesion 
revascularisation; TVR: target vessel revascularisation
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Impact on daily practice
There is an unmet need in primary and secondary cardiovascular 
prevention. Ultimately PCI should open the door towards opti-
mising secondary prevention. The SYNTAX (SX-) score, based 
on simple baseline angiographic criteria, predicts procedural 
risk and annual rates of major adverse cardiovascular events 
among patients undergoing PCI. Up to two thirds of patients 
undergoing PCI for SIHD (SX-score >8) in routine clinical prac-
tice have a higher risk of MACE than ACS patients. It remains to 
be determined whether they would benefit from more intensive 
anti-platelet therapy.
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